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Angiotensin receptor blockers (ARBs) are antihypertensive medications, prescribed especially for patients with coexistent diabetes mellitus [1]. Their mechanism of action 
is inhibition of angiotensin II and angiotensin II - receptor interaction, 
leading to decreased effect of angiotensin II. This suppresses renin–
angiotensin system (RAS). ARBs, as well angiotensin-converting 
enzyme (ACE) inhibitors [2], are contraindicated during pregnancy, 
due to the high incidence of fetal complications such as anuria, 
renal tubular dysplasia, renal insufficiency, oligohydramnios, 
malformations, and intrauterine death after maternal exposure.
CASE REPORT
We report a 4-day-old 30 weeks, appropriate for gestational age 
neonate, presented with complaints of not voided urine since birth. 
Baby was born to 30-year-old G5P2L2A2 mothers with no antenatal 
risk factors. All antenatal scans until 23 weeks of gestational 
age were normal. At 30 weeks, ultrasound study showed severe 
oligohydramnios with amniotic fluid index <1 cm. Doppler study 
was within normal limits. There was no preterm premature rupture 
of membrane or any features suggestive of chorioamnionitis. 
In view of severe oligohydramnios, baby was delivered by 
emergency lower section cesarean section after administering 
two doses of antenatal steroids. Baby cried immediately after 
birth and Appearance, Pulse, Grimace, Activity, and Respiration 
scores were normal. Birth weight was 1.4 kg which was between 
10th and 50th centile as per Fenton’s chart. Baby was appropriate 
for gestational age with no features of growth restriction. Serum 
creatinine at 18 h of life was 1.3 mg/dl with no urine output. 
Medical management was initiated with fluid restriction and with 
correction of dyselectrolytemia. Fluid requirement was calculated 
according to insensible water losses and urine output which was 
assessed every 6 h. By 72 h of life serum creatinine increased to 
3.9 mg/dl along with serum potassium of 6.9 mEq/L and serum 
sodium of 129 mEq/L. Baby was started on salbutamol nebulization 
and intravenous calcium gluconate injection. Baby was started on 
peritoneal dialysis by 76 h of life. Serial investigation reports are 
summarized in Table 1. Ultrasound study of the abdomen with 
careful evaluation of kidney, ureter, and bladder was within normal 
limits. On careful and meticulous history review, it was found that 
mother was taking Olmesartan medoxil 20 mg once daily and the 
cause of acute kidney injury was attributed to antenatal exposure 
of ARBs medication. Mother is not suffering from hypertension, 
and she did not have a prescription for the drug. She stated that 
she purchased this drug over the counter for complaints of gastritis 
and she never knew that it is an antihypertensive medication. Baby 
started voiding urine by day 5 of peritoneal dialysis and catheter 
was removed by day 10 of peritoneal dialysis as the urine output 
was >1 ml/kg/hour and renal parameters and serum electrolytes 
were within normal limits. However, by day 15 of life, baby 
started developing features of nosocomial infections (sepsis and 
peritonitis), and baby expired on day 19 of life in spite of adequate 
antibiotic coverage.
DISCUSSION
Experiments on animals and human reports have described 
fetal anomalies, fetal anuria with renal abnormalities, stillbirth, 
ABSTRACT
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) are widely used antihypertensive with 
well-recognized renoprotective and cardioprotective effects. Although treatment with these agents generally does not result in 
adverse metabolic consequences, their use during human pregnancy has been associated with negative reactions. Here, we report a 
premature baby with a history of oligohydramnios and maternal exposure to the ARB olmesartan medoxomil who was transferred 
to our institution with acute renal failure.
Key words: Acute renal failure, Oligohydramnios, Olmesartan medoxomil
Dathan and Lakhshmi Olmesartan medoxomil-induced acute renal failure in newborn
Vol 4 | Issue 2 | Mar - Apr 2018 Indian J Case Reports 106
and neonatal death following maternal treatment with ARBs 
and ACE inhibitors during pregnancy. In the literature, 
unfavorable fetal outcomes following exposure during late 
pregnancy are disturbingly frequent. As is also well known for 
ACE inhibitors [2], the gestational age of a fetus exposed to 
ARBs is of great importance, with kidney lesions appearing 
in the second part of the pregnancy [3]. The expression of the 
angiotensin receptor II gene could be considered the reason for 
this critical gestational window for the drug-induced renal lesion. 
The acquired abnormality in renal function due to olmesartan 
medoxomil exposure seems, therefore, not necessarily lethal. The 
recovery of renal function observed in our patient suggests that 
fetal renal damage may be reversible for a period whose length 
is perhaps gestational age - and dose-dependent. As there is no 
evidence to identify safely the length of this reversibility period, 
withdrawal of ARBs must still be considered at the earliest 
time possible in pregnancy. Fetotoxic effects of angiotensin-II 
receptor antagonist losartan were first reported in 2001. These 
were similar to those seen in exposure to ACE inhibitors during 
pregnancy [4]. Abnormalities are oligohydramnios, pulmonary 
hypoplasia, hypoplastic skull bones, and limb contractures, 
with subsequent fetal or neonatal death [4-6]. The expression of 
angiotensin II receptors is less during the initial stages of renal 
development and increases later in pregnancy in mature renal 
tissues [5]. Adequate amniotic fluid is necessary for normal 
fetal lung maturation. Hence, oligohydramnios due to any 
cause may result in pulmonary hypoplasia. Fetal membranous 
bones are highly vascular and require high oxygen tension for 
growth [5]. Possible reason of skull hypoplasia is decreased 
in fetal blood flow due to reduced activity of the RAS. It may 
cause low oxygen supply, which may inhibit mineralization and 
ossification of the skull. Oligohydramnios may further cause the 
uterine muscles to exert a direct impact on the developing fetal 
skull, which may interfere with skull ossification [7]. In a study 
of 15 newborns with maternal intake of ARB’s in the second/
third trimester, the outcome was poor as 6 (40%) cases died due 
to severe hypotension, pulmonary hypoplasia, and anuria. Renal 
failure improved with treatment in only 3 (20%). Hypoplastic 
and poorly ossified skull bones and widely open sutures were 
seen in 9 cases [6]. In another case report, fetal ultrasound at 
29 weeks gestation suggested oligohydramnios with normal fetal 
kidneys. Stopping olmesartan, maternal rehydration along with 
furosemide reversed the renal impairment. Baby was born at term 
with normal renal function, suggesting that renal impairment due 
to olmesartan may be reversible [8]. In a similar study of seven 
newborns, oligohydramnios was present in all, and fetal kidneys 
were hyperechogenic on ultrasound. Four did not survive, 2 
had renal impairment requiring chronic dialysis, and only 1 had 
complete recovery of renal functions. Other features seen in these 
patients were cranial ossification defect, flaccid paralysis of 
hands and feet and sensorineural hearing loss [9].
CONCLUSION
Fetal exposure to ACE-Is or ARBs has relevant neonatal and 
long-term complications. The neonatal outcome appear to be poorer 
following prenatal exposure to ARBs compared with ACE-Is. 
30 years after the first description of ACE inhibitor-induced 
fetopathy, relevant complications are regularly described, 
indicating that the awareness of the deleterious effects of prenatal 
exposure to drugs inhibiting the RAS should be addressed.
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Table 1 : Serial investigation reports
Investigations Day 1 of life Day 3 of life Day 5 of life Day 7 of life Day 10 of life
Blood urea (mg/dl) 110 185 160 95 66
Serum creatinine (mg/dl) 1.3 3.9 2.6 1.3 0.8
Serum sodium (Meq/L) 138 130 134 138 140
Serum potassium (Meq/L) 4.2 6.9 5.8 4.2 4
Urine output (ml/kg/hour) 0 0 0 0.6 1.2
